Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Expects To File 12 "Major" NDAs By The End Of 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.

You may also be interested in...

Pfizer/Boehringer’s Spiriva Captures 10% Share Of New Prescriptions

Pfizer and Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (tiotropium) has a 10% share of new prescriptions.

Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety

The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.

Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity

FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts